The drug development pipelines for new antibiotics have been drying up in recent years just as new challenges from war zones are appearing (resistant gram negative (G-)bacteria such as acinetobacter and imipenim resistant klebsiella sp). Meanwhile methicillin resistant staph aureus (MRSA) is giving away to vancomycin resistant (VRSA) forms among gram positive (G+)bacteria. In many cases there are no drugs available for some multiply resistant G+ and G- strains and those that are have significant toxicity (mostly renal). While G- infections are still primarily hospital based, G+ infections are established in many communities. Although the problem is not new, the slow down in new drug development is. The following article discusses the issues.
EDIT: I decided to post this after reading about a civilian in the US who just died of acinetobacter infection. It was on the Yahoo home page today. I went back to check it, and it was gone. Perhaps someone else saw it.